Probably end up on the OTC imo. They're bleeding themselves and must realize it by now. I'm not sure they can do a RS and maintain compliance without some serious funding. Which will likely be toxic.
just my guess. But, it can still be playable with the volatility.
All on thge ask @ .48...
0.48
132700
batx
0.48
132700
edgx
0.48
132700
NSDQ
0.48
132700
arcx
Crazy. Shorts are certainly taking advantage.
IMO
just my guess. But, it can still be playable with the volatility.
All on thge ask @ .48...
0.48
132700
batx
0.48
132700
edgx
0.48
132700
NSDQ
0.48
132700
arcx
Crazy. Shorts are certainly taking advantage.
IMO
Do your research! Play the TA. All posts are my opinion.
Is fundamental trading dead?
"We hope not." Richard Dennis
Recent EVAX News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/17/2026 07:30:06 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/17/2026 07:20:06 PM
- Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial • GlobeNewswire Inc. • 04/17/2026 07:10:00 PM
- New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma • GlobeNewswire Inc. • 04/17/2026 07:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/16/2026 04:00:14 PM
- Evaxion concludes Annual General Meeting • GlobeNewswire Inc. • 04/16/2026 03:30:00 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 04/10/2026 08:20:54 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/07/2026 12:05:06 PM
- Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01 • GlobeNewswire Inc. • 04/07/2026 12:00:00 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 04/02/2026 08:06:38 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 04/02/2026 12:55:35 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/30/2026 12:05:06 PM
- Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress • GlobeNewswire Inc. • 03/30/2026 12:00:00 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 03/27/2026 09:09:43 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 03/27/2026 09:09:14 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/19/2026 01:10:04 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/19/2026 01:00:05 PM
- Notice to convene Evaxion’s Annual General Meeting • GlobeNewswire Inc. • 03/19/2026 01:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 01:12:04 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 01:11:27 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 01:07:58 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 01:06:30 AM
